Advertisement

Annals of Hematology

, Volume 97, Issue 4, pp 597–604 | Cite as

Chronic myeloid leukemia patients in Tunisia: epidemiology and outcome in the imatinib era (a multicentric experience)

  • Raihane Ben LakhalEmail author
  • Hela Ghedira
  • Hatem Bellaaj
  • Yosra Ben Youssef
  • Samia Menif
  • Zeineb Manai
  • Manel Bedoui
  • Amel Lakhal
  • Fehmi M’Sadek
  • Moez Elloumi
  • Abderrahmane Khélif
  • Neila Ben Romdhane
  • Mohamed Adnène Laatiri
  • Tarek Ben Othmen
  • Balkis Meddeb
Original Article

Abstract

Data are limited in developing countries regarding the clinicopathologic features and response to therapy of chronic myeloid leukemia (CML) in the era of imatinib (IM). The objective of this study is to report on the clinicoepidemiologic features of CML in Tunisia, to evaluate the long-term outcome of patients in chronic (CP) or accelerated phase (AP) treated with IM 400 mg daily as frontline therapy, and to determine imatinib’s efficacy and safety. From October 2002 to December 2014, 410 CML patients were treated with IM in six Tunisian departments of hematology. Response (hematologic, cytogenetic, and molecular responses) and outcome—overall survival (OS), event-free survival (EFS), and progression-free survival (PFS)—were evaluated. The following prognostic factors were analyzed for their impact on the European leukemia net (ELN) response, OS, EFS, and PFS at 5 years: age, sex, leukocyte count, Sokal score, European Treatment and Outcome Study (EUTOS) score, CML phase, time to starting IM, and impact of adverse events. The median age was 45 years (3–85 years). Two hundred ten (51.2%) patients were male. Splenomegaly was present in 322 of the 410 (79%). Additional cytogenetic abnormalities were encountered in 25 (6.3%) patients. At diagnosis, 379 (92.4%) patients were in CP, 31 (7.6%) were in AP. The Sokal risk was low in 87 (22.5%), intermediate in 138 (35.7%), and high in 164 patients (41.9%). The EUTOS risk was low in 217 (74%), and high in 77 (26%) patients. The rates of cumulative complete cytogenetic response (CCyR), major molecular response (MMR), and molecular response 4/5 log (MR4.5) in CP/AP-CML patients were 72, 68.4, and 46.4%, respectively. The median time to reach CCyR, MMR, and MR4.5 was 6 months (3–51), 18 months (3–72), and 24 months (3–100), respectively. According to the ELN criteria, optimal, suboptimal response, and failure were noted in 206 (51.8%), 61 (15.3%), and 125 (31.4%) patients, respectively. Five-year event-free survival (EFS), progression-free survival (PFS), and overall survival (OS) were 81, 90, and 90%, respectively. By multivariate analysis, AP, high EUTOS risk, and baseline WBC ≥ 150G/l remained independent predictive factors of non-optimal response to IM. The adverse events (AE) of IM were moderate and tolerable. With the caveats that the monitoring of the disease was not optimal, response rates were similar to those reported in previous studies. It is clear to us that improvements should be made in treatment of AP-CML and high Sokal risk group of CP-CML. The frontline use of second-generation tyrosine kinase inhibitor (TKI) is expected to improve the results of the first-line treatment of these high-risk Tunisian patients, but cost and accessibility of this therapy remain the problems in developing countries.

Keywords

Tunisia Clinical practice CML Imatinib Management Survey 

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Aziz Z, Iqbal J, Akram M, Saeed S (2007) Treatment of chronic myeloid leukemia in the imatinib era perspective from a developing country. Cancer 109(6):1138–1145.  https://doi.org/10.1002/cncr.22498 CrossRefPubMedGoogle Scholar
  2. 2.
    Dong-Wook K, Shripad DB, Udomsak B et al (2010) Chronic myeloid leukemia in the Asia-Pacific region: current practice, challenges and opportunities in the targeted therapy era. Leuk Res 34:1459–1471CrossRefGoogle Scholar
  3. 3.
    Cortes JE, Talpaz M, O’Brien S et al (2006) Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the World Health Organization proposal. Cancer 106(6):1306–1315.  https://doi.org/10.1002/cncr.21756 CrossRefPubMedGoogle Scholar
  4. 4.
    Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, Apperley J, Cervantes F, Cortes J, Deininger M, Gratwohl A, Guilhot F, Horowitz M, Hughes T, Kantarjian H, Larson R, Niederwieser D, Silver R, Hehlmann R, European LeukemiaNet (2006) Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European Leukemia Net. Blood 108(6):1809–1820.  https://doi.org/10.1182/blood-2006-02-005686 CrossRefPubMedGoogle Scholar
  5. 5.
    Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, Cervantes F, Deininger M, Gratwohl A, Guilhot F, Hochhaus A, Horowitz M, Hughes T, Kantarjian H, Larson R, Radich J, Simonsson B, Silver RT, Goldman J, Hehlmann R, European LeukemiaNet (2009) Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. JCO 27(35):6041–6051.  https://doi.org/10.1200/JCO.2009.25.0779 CrossRefGoogle Scholar
  6. 6.
    Baccarani M, Deininger MW, Rosti G et al (2013) European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122(6):872–884.  https://doi.org/10.1182/blood-2013-05-501569 CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Rohrbacher M, Hasford J (2009) Epidemiology of chronic myeloid leukaemia. Best Pract Res Clin Haematol 22(3):295–302.  https://doi.org/10.1016/j.beha.2009.07.007 CrossRefPubMedGoogle Scholar
  8. 8.
    Funke VA, Medeiro CR, Lima DH et al (2005) Therapy of chronic myeloid leukemia with imatinib mesylate in Brazil: a study of 98 cases. Rev Bras Hematol Hemoter 27:159–165CrossRefGoogle Scholar
  9. 9.
    Aguayo A, Garcia-Alvarez E, Cazares-Ordonez Y, Crespo-Solis E, Martinez-Baños D, Guadarrama-Beltran E, Cervera-Ceballos EE, Lopez-Karpovitch X (2008) Chronic myeloid leukemia: a clinicoepidemiologic and therapeutic description of a single institution in Mexico City. Clin Leuk 2(4):261–266.  https://doi.org/10.3816/CLK.2008.n.036 CrossRefGoogle Scholar
  10. 10.
    O’Brien SG, Guilhot F, Larson RA et al (2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348(11):994–1004.  https://doi.org/10.1056/NEJMoa022457 CrossRefPubMedGoogle Scholar
  11. 11.
    Druker BJ, Guilhot F, O’Brien SG et al (2006) Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355(23):2408–2417.  https://doi.org/10.1056/NEJMoa062867 CrossRefPubMedGoogle Scholar
  12. 12.
    Kantarjian HM, O’Brien S, Cortes J et al (2003) Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data. Cancer 98(12):2636–2642.  https://doi.org/10.1002/cncr.11831 CrossRefPubMedGoogle Scholar
  13. 13.
    Rodrigues Lemos JA, Quinto Bentes A, Simões Beltrão AC et al (2010) Late diagnosis and delayed treatment combined as a cause of suboptimal response to imatinib in chronic myeloid leukemia in developing countries, 116. Blood, Dent Abstr 4750Google Scholar
  14. 14.
    Hasford J, Baccarani M, Hoffmann V, Guilhot J, Saussele S, Rosti G, Guilhot F, Porkka K, Ossenkoppele G, Lindoerfer D, Simonsson B, Pfirrmann M, Hehlmann R (2011) Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood 118(3):686–692.  https://doi.org/10.1182/blood-2010-12-319038 CrossRefPubMedGoogle Scholar
  15. 15.
    Zelada J, Capurro MPA, Rojas B et al (2013) Is EUTOS score predictive of outcome in patients with early chronic phase chronic myeloid leukemia treated with imatinib? Preliminary data from the National Protocol of the Chilean Cooperative Group Panda. Blood 122(21):5196Google Scholar
  16. 16.
    Oyekunle AA, Osho PO, Aneke JC et al (2012) The predictive value of the Sokal and Hasford scoring systems in chronic myeloid leukaemia in the imatinib era. J Hematol Malig 2:25–32Google Scholar
  17. 17.
    Tauchi T, Kizakib M, Okamotoc S et al (2011) Seven-year follow-up of patients receiving imatinib for the treatment of newly diagnosed chronic myelogenous leukemia by the TARGET system. Leuk Res 35(5):585–590.  https://doi.org/10.1016/j.leukres.2010.10.027 CrossRefPubMedGoogle Scholar
  18. 18.
    Kantarjian HM, Larson RA, Cortés JE, Deering KL, Mauro MJ (2013) Current practices in the management of chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk 13(1):48–54.  https://doi.org/10.1016/j.clml.2012.07.009 CrossRefPubMedGoogle Scholar
  19. 19.
    Hehlmann R, Lauseker M, Jung-Munkwitz S, Leitner A, Müller MC, Pletsch N, Proetel U, Haferlach C, Schlegelberger B, Balleisen L, Hänel M, Pfirrmann M, Krause SW, Nerl C, Pralle H, Gratwohl A, Hossfeld DK, Hasford J, Hochhaus A, Saußele S (2011) Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia. J Clin Oncol 29(12):1634–1642.  https://doi.org/10.1200/JCO.2010.32.0598 CrossRefPubMedGoogle Scholar
  20. 20.
    Lapusan S, Yong A, Savani BN et al (2014) Achieving early molecular response in chronic myeloid leukemia in chronic phase to reduce the risk of progression: clinical relevance of the 3- and 6-month time points. Eur J Haematol 95:103–111CrossRefPubMedGoogle Scholar
  21. 21.
    Jain P, Kantarjian H, Nazha A, O'Brien S, Jabbour E, Romo CG, Pierce S, Cardenas-Turanzas M, Verstovsek S, Borthakur G, Ravandi F, Quintas-Cardama A, Cortes J (2013) Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities. Blood 121(24):4867–4874.  https://doi.org/10.1182/blood-2013-03-490128 CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Raihane Ben Lakhal
    • 1
    Email author
  • Hela Ghedira
    • 2
  • Hatem Bellaaj
    • 3
  • Yosra Ben Youssef
    • 4
  • Samia Menif
    • 5
  • Zeineb Manai
    • 6
  • Manel Bedoui
    • 7
  • Amel Lakhal
    • 8
  • Fehmi M’Sadek
    • 2
  • Moez Elloumi
    • 3
  • Abderrahmane Khélif
    • 4
  • Neila Ben Romdhane
    • 6
  • Mohamed Adnène Laatiri
    • 7
  • Tarek Ben Othmen
    • 8
  • Balkis Meddeb
    • 9
  1. 1.Hematology DepartmentAziza Othmana University HospitalTunisTunisia
  2. 2.Hematology DepartmentMilitary Hospital TunisTunisTunisia
  3. 3.Hematology DepartmentHedi Chaker HospitalSfaxTunisia
  4. 4.Hematology DepartmentFarhat Hached HospitalSousseTunisia
  5. 5.Biology, Institut PasteurTunisTunisia
  6. 6.Hematology DepartmentLa Rabta HospitalTunisTunisia
  7. 7.Hematology DepartmentFattouma Bourguiba HospitalMonastirTunisia
  8. 8.Centre national de greffe de moelle osseuseTunisTunisia
  9. 9.Department of HaematologyAziza Othmana University HospitalTunisTunisia

Personalised recommendations